Troy Asset Management Ltd reduced its stake in CME Group Inc. (NASDAQ:CME - Free Report) by 8.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 587,896 shares of the financial services provider's stock after selling 56,290 shares during the quarter. CME Group comprises approximately 3.7% of Troy Asset Management Ltd's portfolio, making the stock its 8th biggest holding. Troy Asset Management Ltd owned approximately 0.16% of CME Group worth $115,580,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. Bluefin Capital Management LLC purchased a new position in CME Group during the fourth quarter worth about $2,891,000. Alaska Permanent Fund Corp lifted its position in CME Group by 81.4% during the first quarter. Alaska Permanent Fund Corp now owns 44,534 shares of the financial services provider's stock worth $9,588,000 after buying an additional 19,985 shares during the period. Oak Harvest Investment Services lifted its position in CME Group by 66.5% during the first quarter. Oak Harvest Investment Services now owns 45,093 shares of the financial services provider's stock worth $9,708,000 after buying an additional 18,017 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in CME Group by 21.2% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 48,205 shares of the financial services provider's stock worth $9,477,000 after buying an additional 8,443 shares during the period. Finally, Sierra Summit Advisors LLC purchased a new position in CME Group during the fourth quarter worth about $1,184,000. 87.75% of the stock is currently owned by hedge funds and other institutional investors.
CME Group Stock Performance
NASDAQ:CME traded up $4.63 during trading hours on Tuesday, reaching $225.28. 2,043,417 shares of the stock were exchanged, compared to its average volume of 1,961,065. CME Group Inc. has a 52 week low of $190.70 and a 52 week high of $225.32. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.10. The firm has a 50 day simple moving average of $210.11 and a 200-day simple moving average of $207.42. The stock has a market capitalization of $81.12 billion, a P/E ratio of 25.10, a P/E/G ratio of 8.74 and a beta of 0.55.
CME Group (NASDAQ:CME - Get Free Report) last posted its quarterly earnings data on Wednesday, July 24th. The financial services provider reported $2.56 EPS for the quarter, topping analysts' consensus estimates of $2.53 by $0.03. CME Group had a return on equity of 12.82% and a net margin of 56.98%. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the previous year, the business earned $2.30 EPS. The company's quarterly revenue was up 12.7% compared to the same quarter last year. As a group, sell-side analysts forecast that CME Group Inc. will post 9.94 earnings per share for the current fiscal year.
CME Group Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Wednesday, September 25th. Stockholders of record on Monday, September 9th were given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.04%. The ex-dividend date was Monday, September 9th. CME Group's dividend payout ratio (DPR) is presently 52.33%.
Insider Transactions at CME Group
In other news, Director Bryan T. Durkin sold 7,593 shares of the business's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $214.59, for a total transaction of $1,629,381.87. Following the sale, the director now directly owns 55,607 shares of the company's stock, valued at $11,932,706.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Lynne Fitzpatrick sold 754 shares of the company's stock in a transaction on Sunday, September 15th. The stock was sold at an average price of $216.99, for a total transaction of $163,610.46. Following the transaction, the chief financial officer now directly owns 13,261 shares of the company's stock, valued at $2,877,504.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bryan T. Durkin sold 7,593 shares of the company's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $214.59, for a total value of $1,629,381.87. Following the transaction, the director now directly owns 55,607 shares in the company, valued at $11,932,706.13. The disclosure for this sale can be found here. 0.30% of the stock is owned by insiders.
Analysts Set New Price Targets
Several equities research analysts have commented on the company. Barclays upped their price target on CME Group from $208.00 to $209.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 25th. Deutsche Bank Aktiengesellschaft upped their price target on CME Group from $193.00 to $200.00 and gave the stock a "hold" rating in a research note on Thursday, August 15th. TD Cowen assumed coverage on CME Group in a research note on Thursday, September 26th. They set a "hold" rating and a $221.00 price target for the company. Bank of America lowered CME Group from a "neutral" rating to an "underperform" rating and dropped their price target for the stock from $212.00 to $177.00 in a research note on Tuesday, September 3rd. Finally, Keefe, Bruyette & Woods upped their price target on CME Group from $212.00 to $213.00 and gave the stock a "market perform" rating in a research note on Thursday, July 25th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $212.54.
Get Our Latest Analysis on CME Group
About CME Group
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Further Reading
Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
